<div id="readability-page-1"><p>Albemarle (NYSE:ALB - Get Free Report) announced its quarterly earnings results on Wednesday. The specialty chemicals company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09, FiscalAI reports. The business had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.34 billion. Albemarle had a negative net margin of 0.43% and a positive return on equity of 0.10%.</p><h2>Albemarle Stock Performance</h2><ul><li>MarketBeat Week in Review – 01/12 - 01/16</li></ul><p>Albemarle stock traded up $7.00 during trading hours on Wednesday, reaching $175.56. 3,679,550 shares of the company were exchanged, compared to its average volume of 3,493,575. The company has a current ratio of 2.27, a quick ratio of 1.51 and a debt-to-equity ratio of 0.40. The stock has a 50-day moving average of $155.57 and a 200 day moving average of $113.65. The firm has a market cap of $20.66 billion, a price-to-earnings ratio of -110.41, a PEG ratio of 2.39 and a beta of 1.44. Albemarle has a 12 month low of $49.43 and a 12 month high of $195.68. </p><h2>Institutional Trading of Albemarle</h2><p>A number of institutional investors and hedge funds have recently modified their holdings of ALB. Parallel Advisors LLC grew its position in  Albemarle by 5.7% in the third quarter. Parallel Advisors LLC now owns 2,408 shares of the specialty chemicals company's stock valued at $195,000 after acquiring an additional 129 shares during the period.  Brown Brothers Harriman &amp; Co. lifted its holdings in  Albemarle by 0.9% during the 3rd quarter. Brown Brothers Harriman &amp; Co. now owns 20,700 shares of the specialty chemicals company's stock worth $1,678,000 after buying an additional 189 shares in the last quarter.  Zions Bancorporation National Association UT increased its position in  Albemarle by 7.6% in the fourth quarter. Zions Bancorporation National Association UT now owns 2,697 shares of the specialty chemicals company's stock worth $381,000 after purchasing an additional 191 shares during the period.  MML Investors Services LLC raised its stake in shares of  Albemarle by 1.3% during the second quarter. MML Investors Services LLC now owns 16,991 shares of the specialty chemicals company's stock worth $1,065,000 after buying an additional 217 shares during the last quarter.  Finally, Public Employees Retirement System of Ohio lifted its stake in shares of  Albemarle by 0.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 36,710 shares of the specialty chemicals company's stock valued at $2,976,000 after purchasing an additional 228 shares during the period. 92.87% of the stock is currently owned by institutional investors. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>Albemarle Sits at the Center of Lithium’s Next Cycle</li></ul><p>Several research analysts have weighed in on the company. Zacks Research upgraded Albemarle from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Monday, January 12th. Deutsche Bank Aktiengesellschaft upgraded Albemarle from a &#34;hold&#34; rating to a &#34;buy&#34; rating and increased their target price for the company from $125.00 to $185.00 in a research note on Monday, January 12th. Wells Fargo &amp; Company raised their target price on Albemarle from $135.00 to $174.00 and gave the company an &#34;equal weight&#34; rating in a research note on Monday, January 26th. JPMorgan Chase &amp; Co. increased their price objective on shares of Albemarle from $80.00 to $195.00 and gave the company a &#34;neutral&#34; rating in a research note on Wednesday, January 28th. Finally, Evercore lifted their target price on Albemarle from $88.00 to $100.00 and gave the stock an &#34;in-line&#34; rating in a research report on Tuesday, November 11th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned  a Buy rating, eleven have issued  a Hold rating and two have issued  a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $162.24.</p><p><b>Read Our Latest Analysis on Albemarle</b></p><h2>About Albemarle</h2> (Get Free Report)<ul><li>This ETF Is Up 146% as the Battle Over Rare Earths Heats Up</li></ul><p>Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company's bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.  </p><p>Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world's foremost chemical producers.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Albemarle</li><li>Your Bank Account Is No Longer Safe</li><li>Nvidia CEO Issues Bold Tesla Call</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFMQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFMQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Albemarle Right Now?</h2><p>Before you consider Albemarle, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Albemarle wasn't on the list.</p><p>While Albemarle currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Albemarle Corporation (NYSE:ALB) reported quarterly earnings of ($0.53) EPS, exceeding expectations by $0.09. Revenue reached $1.43 billion, surpassing estimates of $1.34 billion. The company has a positive return on equity of 0.10% and a negative net margin of 0.43%. Institutional investors hold 92.87% of the stock. Analysts have upgraded Albemarle's rating, with a consensus rating of "Moderate Buy" and an average price target of $162.24. The stock traded up to $175.56 during the day, reflecting strong market interest.</p>

Albemarle (NYSE:ALB) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS